Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.

Antibodies to hepatitis A virus (anti-HAV) were measured in children from two separate vaccine trials (n = 70) 4 weeks after a dose of inactivated hepatitis A vaccine (VAQTA). The geometric mean titers (GMTs) of anti-HAV were 49.3 and 45.2 mIU/mL by immunoassay, while reciprocal GMTs of neutralizing anti-HAV were 6.5 and 15.0 by an 80% radioimmunofocus inhibition test (RIFIT) and 55.6 and 92.0 by antigen reduction assay (HAVARNA). The GMT of antibody detected by radioimmunoprecipitation (RIPA) was > or =401. These data establish serologic correlates of protection against disease and show that RIPA is most sensitive for detection of early vaccine-induced antibody. Sera collected from adults (n = 20) 7 days after administration of immune globulin contained similar antibody levels by immunoassay (45.1 mIU/mL) and slightly higher GMTs of neutralizing antibody (27.5 by RIFIT and 146 by HAVARNA) but negligible precipitating antibody (GMT, 5.6). These results are best explained by differences in the affinity of antibodies for virus following active versus passive immunization.

[1]  P. Kunasol,et al.  Protection against hepatitis A by an inactivated vaccine. , 1994, JAMA.

[2]  S. Lemon,et al.  Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate , 1994, Journal of medical virology.

[3]  Lemon Sm,et al.  The value of immunization against hepatitis A , 1994 .

[4]  D. Nalin,et al.  Sensitive assays for hepatitis a antibodies , 1993, Journal of medical virology.

[5]  H. Rotman,et al.  Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization , 1993, Journal of medical virology.

[6]  P. Minor,et al.  Antigenic structure of poliovirus in inactivated vaccines. , 1993, The Journal of general virology.

[7]  A. Delem.  Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. , 1992, Biologicals : journal of the International Association of Biological Standardization.

[8]  B. Wiens,et al.  A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. , 1992, The New England journal of medicine.

[9]  S. Lemon,et al.  Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV. , 1992, Virology.

[10]  P. Winokur,et al.  Immunoglobulin prophylaxis for hepatitis A. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Nalin,et al.  A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. , 1991, The Journal of infectious diseases.

[12]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[13]  E A Emini,et al.  An inactivated hepatitis A viral vaccine of cell culture origin , 1986, Journal of medical virology.

[14]  S. Lemon.  Type A viral hepatitis. New developments in an old disease. , 1985, The New England journal of medicine.

[15]  S. Lemon,et al.  Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. , 1985, Gastroenterology.

[16]  V. Gauss-Müller,et al.  Effect of Hepatitis A Virus Infection on Cell Metabolism in Vitro , 1984, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  S. Lemon,et al.  Serum neutralizing antibody response to hepatitis A virus. , 1983, The Journal of infectious diseases.

[18]  S. Lemon,et al.  Radioimmunofocus assay for quantitation of hepatitis A virus in cell cultures , 1983, Journal of clinical microbiology.

[19]  R. D. Keys,et al.  Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. , 1993, Journal of hepatology.

[20]  D. Nalin,et al.  Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. , 1993, Journal of hepatology.

[21]  S. Lemon,et al.  Genetic, antigenic and biological differences between strains of hepatitis A virus. , 1992, Vaccine.

[22]  J. Finlayson,et al.  Standardization of the antibody to hepatitis A virus (anti-HAV) content of immunoglobulin. , 1983, Developments in biological standardization.